



## New/Changed Dose

## Allergy/Asthma (E-Z) Ebglyss™, Ilaris®, Nucala®, Rinvoq™, Xolair®

## Prescriber Information

Prescriber Name \_\_\_\_\_ MD DO NP PA NPI \_\_\_\_\_  
 Office Contact \_\_\_\_\_ Practice Name / Collaborating MD \_\_\_\_\_  
 Address \_\_\_\_\_ City \_\_\_\_\_ State \_\_\_\_\_ Zip \_\_\_\_\_  
 Phone \_\_\_\_\_ Fax \_\_\_\_\_

## Patient Information • PLEASE SEND COPY OF INSURANCE CARD

Patient's Name \_\_\_\_\_ Last 4 Digits of SS# \_\_\_\_\_ DOB / /  
 Sex M F Weight \_\_\_\_\_ Height \_\_\_\_\_ Diabetic? Y N  
 Address \_\_\_\_\_ City \_\_\_\_\_ State \_\_\_\_\_ Zip \_\_\_\_\_  
 Home Phone \_\_\_\_\_ Work/Cell \_\_\_\_\_ HIPAA Contact \_\_\_\_\_  
 Emergency # \_\_\_\_\_  
 Interpreter Needed? Y N | Allergies Y N If Yes, list allergies \_\_\_\_\_

## Insurance Information

Primary Insurance \_\_\_\_\_ Policy ID \_\_\_\_\_ Group# \_\_\_\_\_  
 BIN \_\_\_\_\_ PCN \_\_\_\_\_  
 Policyholder Name \_\_\_\_\_ Policyholder DOB / /

## Clinical Information • PLEASE SEND COPY OF MEDICAL AND PRESCRIPTION INSURANCE CARDS, PROGRESS NOTES AND LAB REPORTS, SUPPORTING DIAGNOSIS, CO-MORBIDITIES, AND LAB VALUES

**ICD-10/Diagnosis Code** Pulmonary Eosinophilia (J82) Moderate Persistent Asthma, uncomplicated (J45.40) Severe Persistent Asthma, uncomplicated (J45.50) Idiopathic Urticaria (L50.1) Atopic Dermatitis (L20.9) Nasal Polyp (J33.\_\_\_\_\_) Eosinophilic esophagitis (K20) Other \_\_\_\_\_ FEV1 \_\_\_\_\_ %

Pre-treatment serum IgE < 30 IU/mL ≥30-100 IU/mL > 100-200 IU/mL > 200-300 IU/mL  
 > 300-400 IU/mL > 400-500 IU/mL > 500-600 IU/mL > 600-700 IU/mL

Patient medical history includes Positive RAST Positive skin test to perennial aeroallergen  
 Asthma with eosinophilic phenotype Other \_\_\_\_\_

Current maintenance treatment (include dose and frequency) \_\_\_\_\_

Current exacerbation treatment (include dose and frequency) \_\_\_\_\_

Patient is a smoker or is exposed to smoke in the home Y N

Prior Treatment? Y N (Provide Information Below) BSA Affected (%) \_\_\_\_\_

Affected Areas Palms Soles Head Neck Genitalia Other \_\_\_\_\_

Prior Therapy \_\_\_\_\_

Reason for Discontinuation of Therapy \_\_\_\_\_ Approx. Start Date / /  
 Approx. End Date / /

Comorbidities \_\_\_\_\_

Concomitant Medications \_\_\_\_\_

**Prescription Information**

Medication	Quantity/Dose	Sig	Refills
<b>EBGLYSS™</b>	QS for appropriate month of starter dose schedule	Starter Dose Inject 500 mg (two 250 mg injections) SQ at week 0 and 2, then 250 mg SQ every 2 weeks until 16 or later (when adequate clinical response is achieved)	4 Refills
	1 carton (1x250 mg/2 ml)	Maintenance Dose Inject 250 mg SQ every 4 weeks	
<b>NUCALA®</b> *Asthma (12 years and older) & CRSwNP (adults) Pen PFS	1 carton (1x100 mg/ml)	Inject 100 mg SQ once every 4 weeks	
<b>NUCALA®</b> *HES (patients 12 years and older) and EGPA (adults) Pen PFS	3 cartons (3x100 mg/ml)	Inject 300 mg SQ once every 4 weeks	
<b>RINVOQ™</b>	15 mg tablet (30 day supply) 30 mg tablet (30 day supply)	Take 1 tablet by mouth daily	
<b>XOLAIR®</b> *Pen only for use in ages 12+ Pen PFS	Number of 75 mg/0.5 ml pens/syringes _____ Number of 150 mg/ml pens/syringes _____ Number of 300 mg/2 ml pens/syringes _____	Inject _____ mg SQ once every _____ weeks	

**Injection Training**

Patient received injection training      Prescriber's office to provide injection training  
 Community Memorial Healthcare to coordinate injection training

By signing this form and utilizing our services, you are authorizing Community Memorial Healthcare and its employees to serve as your prior authorization designated agent in dealing with medical and prescription insurance companies.

Prescriber Signature \_\_\_\_\_  
 Substitution Permitted  
 Date \_\_\_\_\_

Prescriber Signature \_\_\_\_\_  
 Dispense as Written  
 Date \_\_\_\_\_

If brand is required, please write  
 "DAW" in the box to the right.